Quisinostat (JNJ-26481585) is a novel second-generation HDACi inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. , in NSCLC cells. In vitro, quisinostat has shown anti-proliferative activity against NSCLC cell lines. quisinostat extremely changed protein acetylation patterns of A549 cells and inhibited epithelial-mesenchymal transition (EMT) process.
Quisinostat (JNJ-26481585) is a novel second-generation HDACi inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. , in NSCLC cells. In vitro, quisinostat has shown anti-proliferative activity against NSCLC cell lines. quisinostat extremely changed protein acetylation patterns of A549 cells and inhibited epithelial-mesenchymal transition (EMT) process. Exposure to quisinostat induced mitochondrial injury and increased p53 acetylation, resulting in cell apoptosis and G1 phase arrest. In conclusion, these findings provide the proof of concept for evaluation of quisinostat as a novel NSCLC chemotherapeutic agent. Phase 2.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Hernan Carol, et al. Initial Testing (Stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. Author manuscript; available in PMC 2015 Feb 1. Published in final edited form as: Pediatr Blood Cancer. 2014 Feb; 61(2): 245–252. Published online 2013 Sep 4. doi: 10.1002/pbc.24724.
分子式 C21H28Cl2N6O2 |
分子量 394.48 |
CAS号 875320-31-3 |
储存方式 -20 ℃长期冷藏储存。冰袋运输 |
溶剂(常温) |
DMSO 76 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
15% Captisol 30 mg/mL
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们